Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study.
Marc JB, McCarthy C, Wallis CL, Kityo C, Hughes MD, Godfrey C, Shah NS, Parikh UM, Maartens G, Kanyike F, Van Schalkwyk M, Kihumuro RB, Asiimwe P, Tsikhutsu I, Munyanga C, Some FF, Joseph Y, Flowers T, Mohapi L, Samaneka WP, Mponda K, Rassool MS, Pierre S, Woolley E, Manabe YC, Mellors JW, Flexner C, Koenig SP, Mngqibisa R; ACTG A5381–Hakim Study Team.
Marc JB, et al. Among authors: mccarthy c.
Lancet HIV. 2025 Dec;12(12):e836-e849. doi: 10.1016/S2352-3018(25)00162-6.
Lancet HIV. 2025.
PMID: 41314742